Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients

Prostate

Volumn 57, Issue 2, 2003, Pages 152-159

  Harada, Mamoru ^a   Kobayashi, Kazuhiko ^a   Matsueda, Satoko ^a   Nakagawa, Masami ^a   Noguchi, Masanori ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody; Cytotoxic T lymphocytes; HLA A24; Peptide; Prostate cancer; PSA

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; EPITOPE; GAMMA INTERFERON; HLA A24 ANTIGEN; IMMUNOGLOBULIN G; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBODY FORMATION; EPITOPES; HLA-A ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; MALE; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DONORS;

EID: 0041896235     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10280     Document Type: Article

References (35)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;81:267-268.
3. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-287.
4. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277-288.
5. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Kayashi A, Yamana H, Shirouzu H, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999;59: 4056-4063.
6. Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Itoh K, Yamada A. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor infiltrating lymphocytes of lung cancer. Cancer Res 2000;60: 3550-3558.
7. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000;164:2565-2574.
8. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4: 328-332.
9. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudly ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
10. Marchand M, Van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-230.
11. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318.
12. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clark K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in woman with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19: 2722-2730.
13. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300.
14. Xue BH, Zhang Y, Sosman J, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997;30:73-78.
15. Correale P, Walmsley K, Zaremba S, Zhu MZ, Schlom J, Tsang KY. Generation of human cytotoxic T lymphocyte lines directed against prostate-specific (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-3194.
16. Murphy GP, Tjoa BA, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
17. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38: 73-78.
18. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54-59.
19. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999;40:125-129.
20. Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y, Tobisu K, Noguchi M, Kakizoe T, Itoh K, Wakazugi H. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol 2001;166:1508-1513.
21. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152: 163-175.
22. Rammensee HG, Friege T, Stevanovic S. MHC ligands and peptides motifs. Immunogenetics 1995;41:178-228.
23. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A new culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunl 2002;51:219-228.
24. Ohkouchi S, Yamada A, Imai N, Mine T, Harada K, Shichijo S, Maeda Y, Saijo Y, Nukiwa T, Itoh K. Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens 2002;59:259-272.
25. Lundwell A, Lilija H. Molecular cloning of human prostate specific antigen. FEBS Lett 1989;214:317-320.
26. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
27. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000;164:5508-5514.
28. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-716.
29. Meadows L, Wang W, den Haan JMM, Drijfhout JW, Shabanowitz J, Pierce R, Agulnik AI, Bishop CE, Hunt DF, Goulmy E, Engelhard VH. The HLA-A* 0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997;6:273-281.
30. Kittlesen D, Thompson LW, Gulden PH, Skiller JCA, Colella TA, Shabanowitz JA, Hunt DR, Engelhard VH, Slingluff JC. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development. J Immunol 1998; 160:2099-2106.
31. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Ohkouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001;7:3950-3962.
32. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-836.
33. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT 3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61: 5137-5144.
34. b transgenic mice. Int J Cancer 2002;100:565-570.
35. Imanishi T, Akazawa T, Kimura A. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, editors. HLA 1991. Vol. 1. Oxford, England: Oxford Scientific Publications; 1992. pp 1065-1220.